Autotaxin catalyzes the transformation of lyso-phosphatidylcholine in lyso-phosphatidic acid (LPA). LPA is a phospholipid possessing a large panel of activity, in particular as a motility factor or as a growth signal, through its G-protein coupled seven transmembrane receptors. Indirect evidence strongly suggests that autotaxin is the main, if not the only source of circulating LPA. Because of its central role in pathologic conditions, such as oncology and diabetes/obesity, the biochemical properties of autotaxin has attracted a lot of attention, but confirmation of its role in pathology remains elusive. One way to validate and/or confirm its central role, is to find potent and selective inhibitors. A systematic screening of several thousand compounds using a colorimetric assay and taking advantage of the phosphodiesterase activity of autotaxin that requires the enzymatic site than for LPA generation, led to the discovery of a potent nanomolar inhibitor, [4-(tetradecanoylamino)benzyl]phosphonic acid (S32826). This compound was inhibitory toward the various autotaxin isoforms, using an assay measuring the [ 14 C]lyso-phosphatidylcholine conversion into [ 14 C]LPA. We also evaluated the activity of S32826 in cellular models of diabesity and oncology. Nevertheless, the poor in vivo stability and/or bioavailability of the compound did not permit to use it in animals. S32826 is the first reported inhibitor of autotaxin with an IC 50 in the nanomolar range that can be used to validate the role of autotaxin in various pathologies in cellular models.
role as a motility factor, regardless of its capacity to catalyze lysoPLD activity (undiscovered at that time). Three different strategies to construct autotoxin knockout mice (van Meeteren et al., 2006; Tanaka et al., 2006; Ferry et al., 2007) all led to lethality, suggesting that autotaxin might be the only source of LPA, at least at the earliest stages of the development. It is noteworthy that even a point mutation [T310A, leading to an inactive enzyme, although expressed and structurally intact (Koh et al., 2003) ] was enough to render the knockout lethal (Ferry et al., 2007) . We speculate that the lack of catalytic activity itself was the origin of this lethality. Indeed, without data in vivo, it is hard to predict how the inhibition of a given activity might translate into pathological situations (Maggi et al., 2004) .
To circumvent this problem, we used pharmacological validation in which a compound, with potency toward the target, in vivo stability and specificity, is evaluated on relevant models to validate a therapeutic target. With this goal in mind, we previously reported the cloning and biochemical characterization of the three autotaxin isoforms and attempted to discover inhibitors . This work (in which we screened a small set of compounds, from phosphodiesterase to kinase inhibitor reference compounds) led to the discovery of several compounds (damnacanthal, hypericin) that were of poor specificity and potency; damnacanthal is an inhibitor of virus-induced cell death (Kamata et al., 2006) and hypericin is a mediator of cell death in cancer cells (Buytaert et al., 2008) . Reports have described compounds discovered by using analogs of either the substrate of the lysoPLD reaction or its product (Prestwich et al., 2008 and references therein) . Attempts were also made to discover autotaxin inhibitors by virtual screening (Parrill et al., 2008) , leading to heterocyclic compounds with poor potency (ϳ50% inhibition at 10 M). These studies led to the report of some interesting compounds, albeit with poor potencies (micromolar range) and, sometimes, also with a potency toward the LPA receptor family. Although interesting, we chose to find autotaxin-specific compounds.
In the present work, we report on the assessment and performance of a screening procedure (13,000 diverse compounds) on autotaxin activity (we chose the partially purified ␤ isoform, because it is the one secreted by adipocytes), the characterization of the main hit, S32826, with an IC 50 of 9 nM, its synthesis, its lack of interaction on a large number of molecular off targets, its weak in vivo stability, and its autotaxin inhibiting capacity in various types of cellular experiments.
Materials and Methods

Biological Sources
Adipocyte-Secreted Autotaxin. This material was used for the screening campaign and was prepared from 3T3F442A cellconditioned media, exactly as described in Ferry et al. (2003) . In brief, 3T3F442A adipocytes were washed twice with phosphatebuffered saline to remove serum and incubated (5 ml for a 10-cm diameter plate; 1 ml for a 3-cm diameter plate) in serum-free Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% fatty acid-free bovine serum albumin at 37°C in a humidified atmosphere containing 7% CO 2 . Conditioned media were separated from the cells, centrifuged, and concentrated (approximately 50-fold) using an Amicon Ultracell 10K (Millipore, Billerica, MA). After adjustment of the protein concentration, they were aliquoted and stored at Ϫ20°C before use.
Cloning and Production of Human Autotaxin. The cloning of the human autotaxin isoforms was performed as described previously (Ferry et al., 2003; Giganti et al., 2008) . COS-7 cells (American Type Culture Collection, Manassas, VA) served as the expression system for autotaxin (NIH-MGC accession number: BC003264). Cells were maintained in culture at 37°C under a humidified atmosphere with 5% CO 2 in DMEM supplemented with 10% fetal calf serum (PAA Laboratories, Linz, Austria), penicillin, streptomycin, and 2 mM glutamine (Invitrogen, Carlsbad, CA). Cells were transiently transfected with control or autotaxin-expressing pMC1 plasmids using Lipofectamine and LipofectamineReagent (Invitrogen), according to the manufacturer's instructions. Two days after transfection, the cell layer was washed three times with red phenol-free DMEM supplemented with 2 mM glutamine and incubated at 37°C for 6 h in the same DMEM. After incubation, the conditioned medium was harvested, dialyzed, and concentrated as described previously and then stored at Ϫ20°C until further use.
Purification of the Recombinant Autotaxin. In brief, 13 ml of 10ϫ medium from the COS cell expression system (see Cloning and Production of Human Autotaxin Subsection) were applied (78 ml/h) over a gel filtration column (HiLoad 26/60, Superdex 200 PrepGrade; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) on an fast-performance liquid chromatography system previously equilibrated with a buffer composed of 20 mM HEPES, pH 7.4, 6 mM D(ϩ)-glucose, 1 mM CaCl 2 , and 1.2 mM MgSO 4 . The column was developed with the same buffer. The fractions containing the lyso-PLD activity were pooled and snap frozen at Ϫ80°C.
Autotaxin Assays
Several methods are available to measure autotaxin activity, as reviewed by Morris and Smyth (2007) . Depending on the purpose of the various experiments of the present study, the following different methods were used.
Measurement of LysoPLD Activity. LysoPLD activity was measured as the conversion of radiolabeled LPC into radiolabeled LPA as described previously (Bétuing et al., 1997) with minor modifications. A solution of [ 14 C]palmitoyl-lyso-phosphatidylcholine (55.8 mCi/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA) at 2.5 nCi/l in DMEM supplemented with 1% fatty acid-free bovine serum albumin was first prepared, and 20 l of this solution was incubated with 500 l of conditioned medium supplemented with 1 l of sodium orthovanadate (0.5 mM) for 90 min at 37°C. At the end of the incubation period, the phospholipids were extracted with 500 l of 1-butanol, evaporated, spotted on silica gel 60 TLC glass plates (Merck, Darmstadt, Germany), and separated using CHCl 3 /MeOH/NH 4 OH (60:35:8) as the migration solvent. The plates were autoradiographed overnight at -80°C using a Biomax MS film (Carestream Health, Paris, France) to localize radiolabeled LPA spots, which were then scraped and counted with 3 ml of scintillation cocktail.
Fluorogenic Enzymatic Assay. Because most of the tests were run on a partially purified protein preparation, we used the simple method described by Gijsbers et al. (2003) . This assay was designed on the basis of the Amplex Red PLD Assay Kit (Interchim, Montluçon, France) originally designed for the measurement of the PLD activity. In this enzyme-coupled assay, PLD cleaves phosphatidylcholine to yield choline and phosphatidic acid. The choline produced by the reaction was in turn oxidized by choline oxidase into betaine and H 2 O 2 . Finally, H 2 O 2 reacted, in the presence of horseradish peroxidase, with Amplex Red to generate resorufin, a compound measured by fluorescence. For the measurement of lysoPLD activity, the assay was modified by replacing phosphatidylcholine with lysopalmitoylphosphatidylcholine (Sigma-Aldrich, St. Louis, MO). The assay was performed in 50 mM Tris/HCl and 5 mM CaCl 2 , pH 8.0, with purified lysoPLD in 96-well plates. The reaction was started by the addition of 100 l of the Amplex Red mixture (lyso-palmi-toylphosphatidylcholine, oleoyl 500 M, choline oxidase, horseradish peroxidase, and Amplex Red reagent). After a 30-min incubation at 37°C, the fluorescence was measured with a spectrofluorimeter (POLARstar Galaxy; BMG Labtech GmbH, Offenburg, Germany) using filters for excitation and emission at 530 and 590 nm, respectively.
Phosphodiesterase Enzymatic Assay. The phosphodiesterase activity of autotaxin was measured using a modification of the method of Razzell and Khorana (1959) . Samples (20 l) were incubated in 1.8-ml microtubes in a final volume of 100 l containing p-nitrophenylphosphonate (pNppp) at a final concentration of 5 mM in a 50 mM Tris-HCl, pH 9.0, buffer. After 30 min at 37°C, the reactions were stopped by the addition of 100 l of 0.1 M NaOH solution. The reaction product was measured by reading the absorbance at 410 nm.
Quantification of LPA. Quantification of LPA was performed using a radioenzymatic assay as described previously (SaulnierBlache et al., 2000) . Phospholipids were extracted from CM (500 l) or plasma (25 l) with 1 volume of 1-butanol followed by evaporation of the solvent under nitrogen. Dried phospholipids were solubilized in 200 l of reaction medium [1 l of [ 14 C]oleoyl-CoA (RAS 55 mCi/mmol; NEN), 20 l of Tris, pH 7.5, 10 l of 200 mM semipurified lyso-phosphatidic acid acyl transferase (Kume and Shimizu, 1997) , 8 l of 500 M sodium orthovanadate, and 161 l of H 2 O (containing 1 mg/ml Tween 20)] and incubated for 120 min at 20°C. The mixture was vortexed every 15 min. The reaction was stopped by addition of 400 l of 12 N CHCl 3 /MeOH/HCl (1:1:0.26) followed by a vigorous shaking and 10-min centrifugation at 3000g. The lower CHCl 3 phase was evaporated under nitrogen, resuspended in 20 l of CHCl 3 / MeOH (1:1), spotted on a silica gel 60 TLC glass plate (Merck), and separated using CHCl 3 /MeOH/NH 4 OH/H 2 O (65:25:0.9:3) as a solvent. The plate was autoradiographed overnight to localize the [ 14 C]phosphatidic acid spots, which were then scrapped and counted with 3 ml of scintillation cocktail.
High-Throughput Screening Assessment and Robotic Workflow. All the experiments necessary to address the stability of the enzyme activity in the robotic conditions were performed. The robot was custom-built by Caliper Zymark (Hopkinton, MA) around a Twister II (Caliper Zymark) arm, with the following peripheral stations: incubator (Liconic Instruments, Woburn, MA) to perform incubation at 37°C; refrigerated incubator (Zymark) to store enzyme and substrate at 4°C; multidrop 96/384 microplate dispenser (Thermo Fisher Scientific, Waltham, MA) to dispense stop solutions; and a 96/384-head dispensing Rapid Plate (Zymark) to dispense enzyme first and substrate next. The optical density was determined by Pherastar at 410 nm (BMG Labtech). The workflow was automatic, and assays for 35 96-well plates (80 compounds per 96-well plate, 2800 compounds per run) were performed simultaneously. The limitation in number of plates was due not to a lack of robot space but to the stability of autotaxin solution at 4°C.
Synthesis of S32826. The three steps of the synthesis of this compound were as follows (see Fig. 3 ): production of diethyl [4-(tetradecanoylamino)benzyl]phosphonate (3). To a solution of diethyl (4-aminobenzyl)phosphonate 2 (10.0 g, 41.11 mmol) and triethylamine (6.35 ml, 45.18 mmol) in CH 2 Cl 2 (300 ml) was added dropwise a solution of tetradecanoyl chloride 1 (11.17 ml, 41.11 mmol) in CH 2 Cl 2 (100 ml), and the reaction was stirred at room temperature for 2 h. A solution of 0.5 N HCl (100 ml) was added, and the mixture was extracted with CH 2 Cl 2 , washed with H 2 O and brine, and dried (MgSO 4 ) to give, after evaporation of the solvent, a white solid that was suspended in diethyl ether and filtered off to give the pure title compound 3 (18.1 g, 97% [4-(tetradecanoylamino) benzyl]phosphonic acid (4). Bromotrimethylsilane (5.82 ml, 44.10 mmol) was added to a suspension of the above phosphonodiester 3 (5.0 g, 11.02 mmol) in CH 3 CN (50 ml), and the mixture was stirred to reflux for 1 h. The resulting solution was evaporated to dryness in vacuo, and the oily residue was taken up in MeOH. The resulting precipitate was stirred for 30 min and was filtered off to give phosphonic acid 4 as a white solid (2.3 g, 52% 
In Vitro and in Vivo Behavior and Biopharmaceutical Properties of S32826
Stability and Membrane Permeability of 32826. All the experiments describing the permeability and metabolic stability of S32826 on rat and human microsomes were performed as described in Bertrand et al. (2000) .
Biopharmacy Studies of S32826. C57BL/6 mice were treated with 10 mg/kg S32826 by oral, intraperitoneal, subcutaneous, and intravenous routes. Blood samples were collected by cardiac puncture under anesthesia, and S32826 plasma concentration was measured 15, 40, 90, and 180 min after oral, intraperitoneal, or subcutaneous administrations and 5, 20, and 60 min after intravenous administration.
Plasma Sample Liquid Chromatography/Tandem Mass Spectrometry Quantification. Plasma collected after administration (four mice per time point) were deproteinized by 2 volumes of acetonitrile and centrifugation, and then analyzed by liquid chromatography/tandem mass spectrometry. The high-performance liquid chromatography column used was a Purospher Star column (2 mm, 15 cm) with an isocratic mobile phase consisting of 20 mM ammonium formate, 0.1% trifluoroacetic acid/acetonitrile (30:70). The tandem mass spectrometry detection was performed in positive electrospray ionization mode (ESIϩ) using a Waters Quattro Ultima (Waters Medical Systems, Rochester, MN), with cone voltage and collision energy set at 80 V and 35 eV, respectively, and following the 398.9 (parent)-106.1 (daughter) multiple reaction monitoring transition.
Cellular and Ex Vivo Experiments
Culture of 3T3-F442A Adipocytes. The mouse preadipocyte cell line 3T3F442A (Green and Kehinde, 1976) was grown in 12-well plates and differentiated as described previously (Bétuing et al., 1997) . In brief, cells were grown to confluence in DMEM supplemented with 10% donor calf serum, and differentiated into adipocytes by culturing them in an adipogenic medium consisting of DMEM supplemented with 10% fetal calf serum plus 50 nM insulin for 10 days. To analyze LPA release, 3T3F442A adipocytes were washed twice with phosphate-buffered saline to remove serum, and incubated in 1 ml of serum-free DMEM supplemented with 1% fatty acid-free bovine serum albumin (Sigma-Aldrich) for 6 h. Conditioned medium was collected and centrifuged to eliminate cell debris and rapidly frozen at Ϫ20°C before LPA quantification.
Culture of Human Adipose Tissue Explants. Human subcutaneous adipose tissue samples were obtained according to the regulation of the Ethical Committee of Faculty Hospital from patients undergoing abdominal dermolipectomy for plastic surgery. The body mass index of the patients varied from 21 to 29 (25.6 Ϯ 1.3, mean Ϯ S.E.M.). No other clinical data were available from these patients. Adipose tissue explants were prepared as described previously (Gesta et al., 2002) . In brief, adipose tissue was carefully dissected out from blood vessels and cut in small pieces (average weight, 20 mg) as described previously. Before use, adipose tissue explants were washed twice in sterile phosphate-buffered saline. To study the release of LPA, adipose tissue explants (1-2 g) were incubated at 37°C in 2 ml of serum-free DMEM supplemented with 1% fatty acid-free bovine serum albumin in a humidified atmosphere contain-
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Experiments with Rat Fat Explants. Epididymal fat (250 mg of 0.5-cm 3 pieces) from male Zucker fatty rats (400 -450 g; Charles River Laboratories, L'Arbresle, France) were incubated in 1 ml of DMEM supplemented with 1% fatty acid-free bovine serum albumin. Incubation was performed for 5 h at 37°C under agitation and 5% CO 2 atmosphere. At the end of the incubation, LPA quantification was performed from 500 l of conditioned media.
Growth Assay. After trypsinization, 1.6 ϫ 10 3 NIH:OVCAR-3 human ovarian carcinoma cells (American Type Culture Collection) were distributed in each well of a 96-well cell culture plate and grown for 48 h in RPMI 1640 medium containing 10% fetal calf serum. The autotaxin inhibitor was added at various concentrations, and the cells were grown for a further 168 h before adding a tetrazolium salt for indirect colorimetric evaluation of cell growth and survival (Mosmann, 1983) .
LysoPLD Activity Measurement. Ascites from mice injected intraperitoneally with 1 ϫ 10 7 OVCAR3 cells were collected at day 20 and their ability to convert lyso-palmitoylphosphatidylcholine (L-1-[palmitoyl-1-14 C]) into LPA was assayed ex vivo (lysoPLD activity) by thin-layer chromatography as described above.
Western Blot. To evaluate the presence of autotaxin in conditioned media and ascites, samples were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes stained with rabbit anti-autotaxin antibody (Cayman Chemical, Ann Arbor, MI) followed by an HRP-conjugated antirabbit antibody (Cell Signaling Technology, Danvers, MA) before chemiluminescence detection of the immuno-complexes.
Results
So far, no specific inhibitor of autotaxin is available. To help in the validation of this potential target, a classic strategy of assay assessment/screening/validations/in vitro and in vivo tests was conducted.
High-Throughput Screening Test Assessment. The colorimetric assay with an artificial substrate (pNppp) for the phosphodiesterase activity of autotaxin, was used to identify inhibitors useful in terms of structures and, possibly, in terms of potency. Furthermore, the method was suitable for automation. The catalytic site responsible for the phosphodiesterase activity is the same as that for the lysoPLD activity (Gijsbers et al., 2003) . The main drawback of this method is that colored compounds might lead to false positives. Therefore, two other methods were assessed to confirm the hits: a fluorescent assay using an enzyme cascade leading to choline oxidase activity measurement (dependent on the release of choline from lyso-phosphatidylcholine) and a TLC method that allows the measurement of the cleavage of the actual, radiolabeled natural substrate of autotaxin: lyso-phosphatidylcholine. We chose to use partially purified autotaxin ␤ secreted from adipocyteconditioned medium for the screening campaign. The stability of the enzyme preparation at room temperature for a maximum of 6 h was checked, and no significant loss of activity was observed (data not shown). This permitted sequential screening of the sublibrary (13,000 compounds) by runs of 35 plates (35 ϫ 80 compounds). Then, the classic tests were made to cope with the format of the assay (96-well plates). The linearity of the signal over time, and over purified autotaxin concentrations, led to the use of 30-min incubations and 2 g/ml enzyme. The signal reaction was stable over 45 min and then decreased slowly during the next 2 h. This implicated that the reading of the reaction in the robotic system had to be done within the first 45 min after the reaction was stopped. Because the compounds were screened at 10 M final and were solubilized in DMSO, the stability of autotaxin activity in the presence of increasing concentrations of this solvent was tested, after which, a loss of signal was observed (ϳ25% DMSO). As shown (Fig. 1A) , the enzyme can tolerate 1.5% DMSO without loss of activity. At that Fig. 1 . Assessment of the colorimetric method for the measurement of autotaxin activity. Influence of DMSO (solvent of the tested compounds) (A) was checked using the pNppp assay for phosphodiesterase activity of autotaxin. For the same assay, the zЈ factor was measured using 96 (B) and 384 (C) well plates. Controls were measured without substrate (bottom lines) whereas 100% assays were measured with pNppp (top lines). stage, it was necessary to design a workflow sheet for the Caliper/Zymark robot that pilots the experiment. The chart is described on Scheme 1. The process was checked by running two sets of standards to insure the continuity of the process. Then, measurements of the zЈ scores were performed in 96-or 384-well plate formats. As shown in Fig. 1, B and C, the zЈ score of the test in the 384-well plate format was not satisfactory because of poor discrimination between active and inactive compounds. The 96-well format, although more tedious, was chosen. The whole library, essentially composed of proprietary molecules, was screened in 2 weeks. All compounds were tested twice at a concentration of 10 M. The global results are presented in Fig. 2 . As can be seen, a large number of hits was obtained. The 200 most active compounds were collected and tested over six concentrations, using the same assay (phosphodiesterase with pNppp). Of those, 76 turned out to be in the 10 M range, 54 were between 1 and 10 M and 61 were in the range of 1 M or below. For many reasons, numerous considerations, among which chemical availability, known pharmacological effects, molecular weight and solubility, we chose the most active compound, S32826, with a 9 nM IC 50 (as identified on Fig. 2 by a star) . The structure of the compound is illustrated in Fig. 3A . A representative mass spectrometry spectrum is shown for the pure compound (Fig. 3B) . Once identified, several tests were run on independent assays, using other methods to assess and validate the initial result.
Activity of S32826 on Pure Autotaxin and Specificity. We used a sigmoid dose response plot to determine the IC 50 of the compound on the purified enzyme.
Once purified to homogeneity, autotaxin is fairly unstable because it precipitates easily and absorbs to plastic or glass surfaces; it has to be stabilized by various adjuvants . We used hexadecyltrimethylammonium bromide (CTAB), a detergent-like compound. Although CTAB has no affinity for the enzyme, it lowers the capacity of S32826 to inhibit autotaxin (Fig. 4, right) , by rightward shifting its IC 50 by 3 logs compared with freshly prepared autotaxin or to autotaxin in concentrated conditioned medium [that does not require adjuvant addition for stability before freezing ]. Likewise, under those conditions, LPA, a natural inhibitor of autotaxin (van Meeteren et al., 2005) completely lacked potency in inhibiting the enzyme activity (Fig. 4, left) . Due to the fact that even inhibition by the product of the reaction was also limited by the treatment with CTAB, we chose to use another adjuvant, 2-methyl-2,4-pentanediol, to stabilize the protein ; under these conditions, IC 50 values were in the nanomolar range (Fig. 4) . Such a shift between IC 50 values obtained with these 2 adjuvants, was also observed when hypericin testing Moulharat et al., 2008) . We then compared the IC 50 values using pure recombinant human autotaxin ␤. As shown in Table 1 , S32826 inhibited autotaxin in the nanomolar range, compared with the inhibitor damnacanthal and LPA . The capacity of S32826 to inhibit autotaxin ␤ was also tested with the three available assays: nucleotidase, lysoPLD/choline oxidase (Gijsbers et al., 2003) , and lysoPLD/TLC, 8.8 Ϯ 0.9, 5.6 Ϯ 0.3, and 47 Ϯ 8 nM, respectively. It is noteworthy that the most direct assay (incubation with LPC, revelation by TLC, and quantification by counting the spots) gave a 1 log rightward shift of the IC 50 , probably because of the use of this particular TLC method, a poorly quantitative assay. S32826 is, by far, the most potent inhibitor of autotaxin described so far.
We then tested the specificity of S32826 toward the three autotaxin isoforms. Unsurprisingly, it had similar IC 50 for the three autotaxin isoforms ) (␣, ␤, and ␥; not shown). The capacity of the compound to inhibit other Scheme 1. Automation chart for the robotic autotaxin assay. Fig. 2 . Histogram of the screening results on autotaxin inhibition. Thirteen thousand compounds were tested at 10 g/ml in the colorimetric assay of autotaxin, using pNppp as the substrate. The details of the assay and its automation are described under Materials and Methods. Twentysix compounds showed more than 50% inhibition at this concentration, corresponding to a hit rate of 0.1%. ‫ء‬ identifies the lead compound chosen for further studies.
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org major processes was evaluated on a series of nonrelated targets, either receptors or enzymes. We then tested the compound on 23 receptors and 6 enzymes, as a ligand or as an inhibitor, respectively, at 0.1 and 10 M. The main targets were: serotoninergic and ␣-adrenergic receptors, lyso-phosphatidic receptor-1, histaminergic and melatoninergic receptors, nicotinic and MCH receptors, PPPAR␥, some kinases, such as met, src, chk1, and glucokinase as well as proteases (endothelin-converting enzyme, angiotensin-converting enzyme) and protein tyrosine phosphatase-1B and phosphodiesterases. The compound showed little activities on most of those targets with the interesting exceptions of the tyrosine protein kinase src (IC 50 ϳ 6 M) and the protein tyrosine phosphatase-1B (IC 50 ϭ 15 M) (data not shown). More importantly, the compound had no affinity up to 10 M for LPA1, the main LPA receptor described in the literature.
Biopharmaceutical Properties of S32826. It was difficult to measure pK values in vitro because of the properties of S32826. The apparently good metabolic stability on microsomes was possibly overestimated because of the low plastic or membrane desorption (metabolic bioavailability prediction higher than 50% in rodents and in man). The apparent very Fig. 4 . Autotaxin inhibition activity of S32826. The compound was resynthesized, analyzed, and tested at 10 concentrations in the phosphodiesterase assay. Its IC 50 , under those conditions, was measured at 1 nM (curve with f). As an example, the adjuvant CTAB was added to prevent the precipitation/aggregation of the enzyme. This compound alters significantly the capacity of S32826 to inhibit autotaxin activity (curve with OE). Likewise, it also alters the capacity of lyso-phosphatidic acid to inhibit its own production. IC 50 values were as follows: with CTAB, no inhibition; without CTAB, 33 Ϯ 10 nM (left); without CTAB, 0.99 Ϯ 0.1 nM; with CTAB, 0.51 Ϯ 0.3 M (right). at ASPET Journals on July 13, 2017 jpet.aspetjournals.org low Caco2 permeability (intestinal absorption prediction lower than 5% based on permeability) could not be ascertained (see Table 2 for details).
As shown in Fig. 5 , concentrations in the range of 2000 ng/ml were reached within the first 20 min after intravenous. administration, whereas 200 ng/ml remained at 180 min (equivalent to 0.5 M) giving an area under the curve of ϳ1700 ng/ml ⅐ h. After oral administration, S32826 was not detected, demonstrating no oral bioavailability. After intraperitoneal and subcutaneous administrations, area under the curve at 180 min values were 330 and 100 ng/ml ⅐ h, respectively, corresponding to approximately 20 and 7% bioavailability, respectively, compared with the intravenous route. The PK profiles obtained with these two last routes were uncommon: very flat for the subcutaneous route, reflecting a slow resorption from the administration site, and very variable with a T max at the last time point (180 min) for the intraperitoneal route, reflecting a low peritoneal resorption. The special behavior after intraperitoneal and subcutaneous administration and the absence of any bioavailability after p.o. administration can be related to the low membrane permeability capability of S32826, together with some possible solubility or dissolution rate limitation. In vivo PK observations were globally in accordance with the in vitro predictions, and the rate of elimination did not seem the prominent reason for short-term activity after intravenous administration.
S32826 Inhibits LPA Release from Adipocytes. Because of the poor score of the autotaxin inhibitor S32826 in vivo and in predicted metabolism/stability, in vitro models were performed using the inhibitor. The lysoPLD activity of autotaxin has been proposed to be responsible for the release of LPA by adipocytes (Boucher et al., 2005) . This hypothesis is based mainly on the existence of a good correlation between the level of expression of autotaxin in adipocytes and the amount of LPA released by the adipocytes (Ferry et al., 2003; Boucher et al., 2005) . As shown in Fig. 6A , S32826 led to a dose-dependent inhibition of the release of LPA by 3T3-F442A adipocytes with an IC 50 of 90 Ϯ 30 nM and a maximal inhibition of 80% at 500 nM. Two compounds served as controls in these experiments: rolipram, a phosphodiesterase IV inhibitor inactive on autotaxin , and compound N, a S32826-related compound with no autotaxin inhibition capacity. Figure 6B depicts a similar system, but obtained from fatty rat epididymal fat explants, using a similar approach. S32826 inhibited LPA release from this tissue in the 200 nM range. The inhibitory action of S32826 on LPA release was also observed with human adipose tissue (Fig. 6C) . These results showed that S32826 potently inhibits the release of LPA from adipocytes. This is the first pharmacological demonstration of the major involvement of autotaxin in the release of LPA by adipocytes.
S32826 Inhibits Plasma Autotaxin Activity. It was proposed that autotaxin might be an important (if not the major) source of circulating LPA (van Meeteren et al., 2006; Tanaka et al., 2006; Ferry et al., 2007) . As previously reported (Tokumura, 2002) , the concentration of LPA present in blood plasma can be increased in vitro by incubating collected plasma at 37°C for a few hours, revealing the existence of an LPA-synthesizing activity (LPA-SA) in plasma that was characterized as a lysoPLD activity. The Fig. 7 shows that incubating (37°C for 6 h) plasma collected from C57BL6/J mice led to a 6.1-fold increase in the initial concentration of LPA. In the presence of S32826 (5 M), the concentration of LPA was increased by only 3.1-fold (i.e., 57% inhibition). These results showed that S32826 potently inhibits plasma LPA-SA in vitro. It also strongly suggests that LPA-SA is largely catalyzed by autotaxin under these conditions. LPA-SA was also measured in plasma from mice that have been treated (intravenous injection) with S32826 (10 mg/kg). As shown in Fig. 8 , a 70% inhibition in plasma LPA-SA was observed 5 min after injection. In contrast, no significant alteration in plasma LPA-SA was observed 30, 60, and 1440 min after injection. These results showed that S32826 transiently inhibits plasma LPA-SA in vivo. In a separate experiment, we observed that 5 min after injection of S32826, the plasma lysoPLD activity, measured by using [ 14 C]LPC as a substrate, was undetectable (n ϭ 3), whereas Caco2 permeability experiment: P app is the apparent permeability calculated from the ratio of compounds appearance in the basolateral compartment (from 0 to 90 min; 20 M incubated) on the initial concentration in the apical compartment. F abs is the human absorbed fraction prediction calculated from a calibration curve performed under the same experimental conditions with references for which human intestinal absorption is defined. The recovery was calculated using the final concentration (90 min) in the apical compartment. Metabolic stability on hepatic microsomes: Cl int is the intrinsic clearance calculated from the compound disappearance curve (between 0 and 60 min, 0.1 M incubated). MF is the metabolic bioavailability prediction (1 Ϫ hepatic extraction ratio) based on total absorption assumption and using the liver well stirred model to extrapolated the hepatic clearance and the extraction ratio to the in vivo situation. The high nonspecific binding was measured comparing the T0 compound concentration to an external unbound sample. For more details, see Bertrand et al. (2000 
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org it was detected in mouse injected with the vehicle (0.54 Ϯ 0.08 pmol/l, n ϭ 3). S32826 Inhibits Autotaxin Activity in Ascitic Fluid. We studied the effect of S32826 in an ovarian cancer model. Like most cell lines in culture, human OVCAR-3 ovarian carcinoma cells do not secrete detectable levels of autotaxin in vitro (not shown). The autotaxin inhibitor S32826 nevertheless exerted a moderate cytostatic, but not cytotoxic, effect on OVCAR-3 growth in vitro as exemplified by the ϳ30% decrease in overall growth at doses up to 50 M (Fig. 9a) .
OVCAR-3 ascites obtained 20 days after intraperitoneal injection in nude mice demonstrated lysoPLD activity (Fig. 9b) and Western blot analyses revealed the presence of autotaxin in the five ascites studied (Fig. 9b, lower part) . Autotaxin production in ascites may result from induction in tumor cells in situ or release from mesothelial cells (Ren et al., 2006) . The lysoPLD activity in the pooled ascites was evaluated in the presence of increasing concentrations of the autotaxin inhibitor S32826. Complete inhibition was observed in the micromolar range with an IC 50 between 10 and 100 nM (Fig. 9c) , a value compatible with the IC 50 found in the molecular autotaxin assays (10 nM). 6 . A, influence of S32826 on LPA release by cultured adipocytes. Ten days after confluent 3T3F442A adipocytes cultured in serum-free DMEM supplemented with 1% bovine serum albumin in the presence of increasing concentrations of S32826. After a 7-h incubation, the conditioned medium was collected and LPA was quantified as described under Materials and Methods. The concentration of LPA in the culture medium obtained in the control condition (100%) was 76 Ϯ 12 nM. Rolipram, a phosphodiesterase IV inhibitor, and compound N, a S32826 distantly related compound inactive on autotoxin, were used as negative controls in these experiments. Values are mean Ϯ S.E.M. of five experiments. B, influence of S32826 on LPA release by fatty rat epididymal adipose tissue explants. C, influence of S32826 at 200 nM on LPA release by human adipose tissue explants. Explants were prepared from human adipose tissue as described under Materials and Methods and incubated in serum-free DMEM supplemented with 1% bovine serum albumin in the presence of various doses of S32826. After 6 h of incubation, the conditioned medium was collected and LPA was quantified as described under Materials and Methods. Values are mean Ϯ S.E.M. of seven experiments; ‫,ءءء‬ P Ͻ 0.001.
816
Ferry et al.
Discussion
Validation of the involvement of an enzyme activity in a physiological or a pathological state can be done using a variety of approaches. We chose to explore the construction of mice invalidated for the target gene and the design/discovery of a molecule as specific and potent as possible. As reported by others and by us, autotaxin deletion leads to lethality (van Meeteren et al., 2006; Tanaka et al., 2006; Ferry et al., 2007) . The first attempts made in our laboratory to help design inhibitors of the enzyme were also frustrating, because autotaxin, despite its close relationship to phosphodiesterases, was poorly sensitive to reference compounds of this family of inhibitors . A screening campaign was launched and led to the discovery of the present first potent inhibitor, S32826. The compound has, nevertheless, a poor bioavailability. Today, drug metabolism and pharmacokinetics tests are part of the drug discovery optimization process, mainly focused on the two oral route barriers, which are the intestine and the liver, using in vitro predictive assays such as Caco2 permeability and microsomal metabolic stability assessments (for review, see Bertrand et al., 2000) . In support of in vivo pharmacology, in vivo pharmacokinetic evaluation is frequently assessed as a complement to the in vitro drug metabolism and pharmacokinetics evaluation. S32826 was very difficult to handle in vitro because 1) reprecipitation in aqueous buffers from a DMSO 10 mM stock solution was observed in the range of 10 to 20 M in medium, but 20 M was soluble in the Caco2 cell medium, including 0.1% bovine serum albumin and 2) plastic or cellular membrane adsorption phenomena were observed, leading to low recoveries reached during in vitro incubations. An explanation could be a possible phospholipid-type behavior when facing biological membranes in aqueous environments. Despite its structure, which was not optimized, and particularly its aliphatic chain, S32826 remains an interesting compound, not only because it is the strongest inhibitor of autotaxin reported so far, but also because it showed activity whenever cellular or ex vivo models were used. Indeed, apart from compounds issued from lipid chemistry, such as LPA phosphonate analogs, fatty alcohol phosphates, cyclic phosphatidic acid, Darmstoff analogs of LPA or substituted LPA analogs or sn-2-aminooxy analogs as well as the recently described FTY720 (van Meeteren et al., 2008) , [fingolimod, an immunosuppressor (Suzuki et al., 1996) ], a single attempt to find small heterocyclic inhibitors of autotaxin has been reported using a virtual screening approach, leading to poorly active compounds with IC 50 in the 10 M range (Parrill et al., 2008) . It might be argued that the myristoyl moiety of S32826 makes the compound a lipid-like compound-or even a phospholipid-like derivative, because it also bears a phosphonate residue of LPA. The main difference between this new autotaxin inhibitor and the enzyme substrate is the simplification of the chemical structure, eliminating all the chiral information present in LPA. It is worth stressing that random screening of a library of diverse compounds led to the discovery of several compounds bearing similar features, S32826 being the most potent. Conversely, myristoylation is a post-translational modification known to address the targeted proteins (Boutin, 1997) as well as small peptides (Nelson et al., 2007) to plasma membranes. Nevertheless, one can also point out that the lyso-phospholipid-like compounds that were synthesized and characterized in the literature as autotaxin inhibitors have the same defaults and were at least a thousand times less potent. Conversely, the use of such compounds in vivo is limited due to their particular affinities for membranes, rendering their use difficult or impossible. Furthermore, some of these LPA-derived compounds have affinity for LPA receptors, a feature that was not the case for S32826.
Because, initially, the focus of our research on autotaxin was directed to adiposity, and because autotaxin is secreted from adipose tissues, we investigated the ability of S32826 to inhibit lysoPLD activity present in the culture media of several models from mice (3T3F442A adipocytes), rat (fatty rat epididymal fat), and human (subcutaneous adipose tissue explants). Further experiments were performed, using mice plasma as a biological source. Incubation of S32826 (5 M) for 6 h led to ϳ60% inhibition of LPA-synthesizing activity and the almost complete loss of lysoPLD activity of the sam- Fig. 9 . In vitro and ex vivo activity of S32826 on ovarian cancer and ascites. A, effect of the autotaxin inhibitor S32826 on the growth of OVCAR-3 cells. The cells were grown for four doubling times in the presence of 10% FCS and the inhibitor at different concentrations. The S32826 compound decreased overall growth at high doses. Cell viability was assayed by MTT assay. Mean Ϯ S.E.M. of three independent experiments. B, five individual samples of ascites were collected at day 20 and the cell-free fractions obtained after centrifugation were evaluated for lysoPLD activity. Varying levels of lysoPLD activity were found. Mean Ϯ S.E.M. of two evaluations of the samples. Bottom, Western blot analysis of autotaxin production revealed with the Cayman rabbit anti-autotaxin antibody. C, the five ascites were pooled and S32826 assayed against lysoPLD activity. Inhibition was found in a range compatible with the potency of S32826 against autotaxin. Mean Ϯ S.E.M. of two evaluations.
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To confirm the short half-life of the product in vivo, a new experiment was performed in mice. Blood samples from mice injected intraperitoneally with 10 mg/kg S32826 were tested for their capacity to synthesize LPA. If the compound has an activity in the short time after injection (5 min), this capacity was limited after 30 min, and nothing after a few hours. Nevertheless, the fact that the compound could be still measured in the plasma puzzled us. Indeed, our understanding of this point is that the compound is either absorbed at membrane levels and is then released over time or that S32826 was adsorbed to circulating proteins, although we were not able to see any significant differences whenever the ability of S32826 to inhibit autotaxin activity was measured in the presence or not of albumin as possible inhibitor (Morishige et al., 2007) . In any case, the fact that minutes after S32826 treatment, circulating autotaxin was no longer inhibited, was interpreted as a major obstacle to its use in vivo.
LPA has an emerging role in cancer (Mills and Moolenar, 2003; Ishii et al., 2004) . LPA and/or autotaxin are known to be elevated in ascites from patients with ovarian cancer (Lee et al., 2008) . Owing the many attributed functions of LPA, notably in promoting proliferation, survival, migration, and angiogenesis, it may play a causative role in ovarian cancer progression . This makes LPA and, accordingly, autotaxin, possible targets for reducing the tumor burden (Umezu-Goto et al., 2004) . No antitumor activity of S32826 was observed in the OVCAR-model of three ovarian tumor cells intraperitoneally xenografted in BALB/C nude mice, when tested at a 10 mg/kg dose: the 20-day long daily treatment with S32826 did not prevent ascites formation and did not reduce ascitic LPA levels in situ (data not shown). This contrasts with the ex vivo observation in which S32826 could fully block the lysoPLD activity. LPA levels are known to be elevated in ascites of patients with ovarian carcinoma and, although other enzymes besides lysoPLD/autotaxin may be responsible for extracellular LPA generation in situ, a recent report showed that the relatively high lysoPLD activity found in human ovarian cancer is mainly due to autotaxin (Morishige et al., 2007) . Whether autotaxin plays a role in ascites growth in ovarian cancer could not be ascertained, at least in the model used, because of the pharmacokinetic limitations of the compound used. Follow-up compounds with similar specificity may help to test a role for autotaxin in ascitic growth or in other settings, as shown for metastasis (Baker et al., 2006) .
In conclusion, we report the discovery and characterization of S32826, the first nanomolar inhibitor of autotaxin. This compound has poor bioavailability and poor behavior in vivo but showed outstanding autotaxin inhibition potency in cellular models. At the molecular level, the discovery and use of S32826 might help understanding its involvement in either oncology or adiposity. For instance, using S32826 might help dissect the precise mechanism by which platelets release LPA to support the progression of bone metastases from breast cancer (Boucharaba et al., 2004) . Developing analogs as drugs for patients could also be envisioned. Our present study opens new routes in the discovery of more stable and/or more bioavailable, potent autotaxin inhibitors. As can be extrapolated from our HTS profile, several other compounds-all with higher IC 50 values than S32826 -might represent interesting challenges for the discovery of a potent autotaxin inhibitor usable in vivo.
